---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-024918"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T17:39:51.718749+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Relmada raises $160M private placement; NDV-01 12-month Phase 2 CR rate 76%

## Summary
- Oversubscribed PIPE financing of ~$160M gross from 29.47M shares at $4.75/share plus pre-funded warrants, expected to close March 11, 2026.
- Proceeds to be used for working capital and advancing R&D of product candidates, including NDV-01.
- NDV-01 Phase 2 in high-risk NMIBC: 12-month complete response rate 76% overall, 80% in BCG-unresponsive patients.
- No Grade 3+ treatment-related adverse events; no patient progressed to muscle-invasive disease or required cystectomy.
- Phase 3 RESCUE program planned for mid-2026 with two registrational pathways: 2L BCG-unresponsive and adjuvant intermediate-risk NMIBC.

## SEC filing metadata
- accession: 0001213900-26-024918
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390026024918/0001213900-26-024918-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390026024918/ea0280436-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-024918
- JSON: https://secwatch.observer/filing/0001213900-26-024918.json
- Plain text: https://secwatch.observer/filing/0001213900-26-024918.txt

## Key facts
- Material Agreements
  RELMADA THERAPEUTICS, INC. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $160.0 million (effective 2026-03-09).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional and accredited investors
  - Value: approximately $160.0 million
  - Effective: 2026-03-09
  source text: On March 9, 2026, Relmada Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1553643/000121390026024918/0001213900-26-024918-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.